<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28147">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740296</url>
  </required_header>
  <id_info>
    <org_study_id>DENIM</org_study_id>
    <nct_id>NCT02740296</nct_id>
  </id_info>
  <brief_title>Depression and Immune Function in Multiple Sclerosis (MS)</brief_title>
  <acronym>DENIM</acronym>
  <official_title>Depression and Immune Function in Multiple Sclerosis (MS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is one of the most common symptoms of multiple sclerosis (MS) with a life-time
      prevalence of major depressive disorder (MDD) of up to 50%. Depression occurs more
      frequently in MS than in other chronic diseases including other neurological and
      inflammatory disorders and may contribute to lower quality of life, cognitive problems,
      difficulties at work, and poorer long term health outcomes. Despite its clinical relevance,
      the biological mechanisms which may be responsible for the high risk for MS patients to
      develop depression are unknown.

      In this observational study, investigators explore the molecular mechanisms responsible for
      the impaired regulation of immune cells in relapsing-remitting (RR) MS patients with
      depression. Investigators will compare the molecular and phenotypical profile of immune
      cells obtained from RRMS patients with clinical depression (n=50), matched MS patients who
      do not suffer from depression (n=50) as well as matched healthy controls (n=50) and matched
      patients with depression but without a comorbid neurological disorder (n=50).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Beck Depression Inventory - II</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RRMS</arm_group_label>
    <description>Relapsing-Remitting Multiple Sclerosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RRMS+MDD</arm_group_label>
    <description>Relapsing-Remitting Multiple Sclerosis and Major Depressive Disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MDD</arm_group_label>
    <description>Major Depressive Disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>RRMS</arm_group_label>
    <arm_group_label>RRMS+MDD</arm_group_label>
    <arm_group_label>MDD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited at neurological outpatient clinics and neurologcial clinics of
        the Charité and neurologists' medical practices.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing remitting MS by McDonald Criteria (for RRMS and RRMS+MDD groups).

          -  Currently meeting diagnostic criteria for Major Depressive Disorder (for MDD and
             RRMS+MDD groups)

          -  Age 18-55.

          -  On stable treatment regime, either untreated or on disease modifying therapy (DMT)
             for &gt; 6 months

        Exclusion Criteria:

          -  Secondary-progressive or primary progressive MS.

          -  Substance abuse for more than 6 months.

          -  Pregnancy

          -  Use of steroids or vaccination or infections in the previous 3 months.

          -  Signs of serious psychiatric pathology other than depression including schizophrenia,
             bipolar disorder or developmental and learning disorders including disorders on the
             autism spectrum

          -  Antidepressant medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedemann Paul, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aline Taenzer, M.Sc.</last_name>
    <phone>+49 30 450 517 796</phone>
    <email>aline.taenzer@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefan M Gold, Prof. Dr.</last_name>
    <email>stefan.gold@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedemann Paul, Prof. Dr.</last_name>
      <phone>+49 30 450</phone>
      <phone_ext>639705</phone_ext>
      <email>friedemann.paul@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Gold, Prof. Dr.</last_name>
      <phone>+49 30 450</phone>
      <phone_ext>517 594</phone_ext>
      <email>stefan.gold@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Friedemann Paul, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Gold, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 20, 2016</lastchanged_date>
  <firstreceived_date>April 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Friedemann Paul</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
